Urine miRNA marker, diagnostic reagent and kit for kidney cancer diagnosis
Patent Information
- Application Number
- CN202280081119.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2021-12-09
- Filing Date
- 2022-12-09
- Publication Date
- 2024-11-08
AI Technical Summary
There is a lack of highly population-specific urinary miRNA biomarkers for the early diagnosis of renal cell carcinoma in the current technology, and existing biomarker combinations are insufficient in terms of detection accuracy and reliability.
This invention provides a combination of urinary miRNA biomarkers for the diagnosis of renal cell carcinoma, selected from eight specific miRNAs (such as hsa-miR-671-3p, hsa-miR-518e-5p, hsa-miR-153-3p, etc.). The expression level of miRNAs in urinary samples is detected by reverse transcription and real-time quantitative polymerase chain reaction (RT-qPCR), and combined with multiple biomarkers for early diagnosis and recurrence monitoring.
It improves the sensitivity and specificity of renal cell carcinoma diagnosis, provides a non-invasive early detection method, and achieves efficient diagnosis and monitoring of renal cell carcinoma by detecting miRNA expression levels in urine, which has significant clinical diagnostic value.
Smart Images

Figure 00000024_0000 
Figure 00000025_0000 
Figure 00000025_0001
Abstract
Description
[0001] FIELD OF THE INVENTION The present invention relates to the field of molecular diagnostics, and more particularly to a urine miRNA marker, diagnostic reagent, and kit for the diagnosis of renal cancer. Background: Renal cell carcinoma (RCC) is a malignant tumor originating from the renal tubular epithelium, accounting for 80-90% of renal malignant tumors. Its incidence ranks third among urinary tract cancers, after prostate cancer and bladder cancer. Clear cell carcinoma is the most common histopathological type of renal cancer, accounting for 75-80% of all RCC cases and causing approximately 90,000 deaths worldwide each year. The incidence of RCC has gradually increased over the past few decades. Although the mortality rate of RCC remains high, it is a treatable disease before metastasis occurs. Clinically, RCC has been shown to be resistant to chemotherapy and radiotherapy, and tumor resection remains the only definitive treatment. Nearly 55% of RCC patients survive after curative nephrectomy. However, the lack of early symptoms, the inability to accurately distinguish between benign and malignant masses through imaging or biopsy, and the challenges of detecting cancer cells at early stages are challenging. Therefore, innovative non-invasive methods for early RCC detection are needed. Recently, a number of molecular markers, such as carbonic anhydrase IX (CAIX), vascular endothelial growth factor (VEGF), hypoxia-inducible factor (HIF), KI67, P53, P2L, PTEN (phosphatase and tensin homolog), E-cadherin, osteopontin, CD44, CXCR4, and other cell cycle and proliferation markers, have been identified. None of these potential RCC biomarkers has significantly improved the predictive accuracy of current prognostic systems, most have not undergone large-scale validation, and their use in routine clinical practice is not recommended. To date, no effective early diagnostic biomarkers for RCC have been identified, resulting in late detection of the disease and poor treatment outcomes. Therefore, identifying RCC biomarkers that can improve early diagnosis and prognosis of RCC patients is an important focus of cancer treatment.miRNAs are short, non-coding RNAs (18-25 nucleotides) that can block protein expression by degrading specific target mRNAs or inhibiting their translation. They participate in regulating life processes such as individual development, apoptosis, proliferation, and differentiation, and play a role similar to oncogenes or tumor suppressor genes in tumorigenesis and progression. miRNA expression profiles are highly tissue-specific, with distinct expression patterns in different tumors. These characteristics make miRNAs potential new biomarkers for tumor diagnosis and therapeutic targets. Although many studies have evaluated miRNA expression in RCC patient tissue and serum, urinary miRNA biomarkers and biomarker combinations that can be used for RCC screening have not yet been determined. For example, patent US10457994B2 discloses a miRNA marker combination that can predict metastasis and prognosis of clear cell renal cell carcinoma, including miR-10b, miR-139-5p, miR-130b, and miR-199b-5p; miR-199b-5p and miR-130b are overexpressed in metastatic RCC, while miR-10b and miR-139-5p are downregulated in metastatic RCC. The document microRNA-210-3p depletion by CRISPR / Cas9 promoted tumorigenesis through revival of TWIST 1 in renal cell carcinoma (Hirofumi Yoshino, et. Oncotarget, 2017, 8(13):20881-20894.) disclosed five miRNA markers that are upregulated in clear cell renal cell carcinoma, namely: miR-885-5p> miR-1274, miR-210-3p, miR-224 and miR-1290. In summary, given that the prior art has not yet clearly determined which single miRNA marker or combination of miRNA markers should be selected for accurate and effective prediction or diagnosis of renal cell carcinoma, and that miRNA marker sample collection methods vary, whether from urine, plasma, or tissue, and are inconclusive, those skilled in the art urgently need to develop a urine miRNA marker combination suitable for renal cancer diagnosis with high population specificity.SUMMARY OF THE INVENTION The present invention aims to provide a urine miRNA marker, diagnostic reagent, and kit for the diagnosis of renal cancer that exhibits higher population specificity than other miRNA markers reported internationally. The disclosed miRNA diagnostic markers and combinations are proposed for the first time and are more reliable than other miRNA molecular markers, providing a novel alternative for renal cancer diagnosis. To address the aforementioned technical issues, the present invention provides the following technical solutions: The present invention provides a urine miRNA marker for the diagnosis of renal cancer, selected from any one or more of the following eight miRNAs: hsa-miR-671-3p, hsa-miR-518e-5p, hsa-miR-153-3p, hsa-miR-21-3p, hsa-miR-331-5p, hsa-miR-885-5p, hsa-miR-4306, and hsa-miR-1-3p. o In some embodiments, the urine miRNA marker can be selected from any one or more of the following seven miRNAs: hsa-miR-671-3p, hsa-miR-518e-5p, hsa-miR-153-3p, hsa-miR-21-3p, hsa-miR-331-5p, hsa-miR-885-5p, and hsa-miR-1-3p. oIn some embodiments, the urine miRNA marker can be selected from any one or more of the following seven miRNAs: hsa-miR-671-3p, hsa-miR-518e-5p, hsa-miR-153-3p, hsa-miR-21-3p, hsa-miR-331-5p, hsa-miR-885-5p, and hsa-miR-4306. In some embodiments, the urine miRNA marker can be selected from any one or more of the following six miRNAs: hsa-miR-671-3p, hsa-miR-518e-5p, hsa-miR-153-3p, hsa-miR-21-3p, hsa-miR-331-5p, and hsa-miR-885-5p. In the present invention, the above-mentioned miRNAs selected from hsa-miR-671-3p, hsa-miR-518e-5p, and hsa-miR-4306 are Urinary miRNA markers composed of at least two of the six miRNAs: hsa-miR-153-3p, hsa-miR-21-3p, hsa-miR-331-5p, and hsa-miR-885-5p, having an AUC value higher than that of a single miRNA (e.g., hsa-miR-518e-5p or hsa-miR13p), include, but are not limited to, the following combinations, which may be used as preferred embodiments:
[0002] 1) Preferably, the urine miRNA marker can be selected from at least two of the following five miRNAs: hsa-miR-671-3p, hsa-miR-518e-5p, hsa-miR-153-3p, hsa-miR-21-3p, and hsa-miR-331-5p o hsa-miR-671-3p> hsa-miR-518e-5p, hsa-miR-153-3p^ hsa-miR-21-3p^ hsa-miR-885-5p0hsa-miR-671-3p> hsa-miR-518e-5p, hsa-miR-153-3p> hsa-miR-331-5p> hsa-miR-885-5p ohsa-miR-671-3p > hsa-miR-518e-5p, hsa-miR-21-3p > hsa-miR-331-5p > hsa-miR-885-5p0hsa-miR-671-3p > hsa-miR-153-3p > hsa-miR-21-3p > hsa-miR-331-5p, hsa-miR-885-5p0hsa-miR-518e-5p > hsa-miR-153-3p > hsa-miR-21-3p > hsa-miR-331-5p > hsa-miR-885-5p0
[0003] 2) Preferably, the urinary miRNA markers can be selected from at least two of the following 4 miRNAs: hsa-miR-671-3p > hsa-miR-518e-5p, hsa- hsa-miR-21-3p o hsa-miR-671-3p > hsa-miR-518e-5p, hsa- hsa-miR-331-5p o hsa-miR-671-3p > hsa-miR-518e-5p, hsa- hsa-miR-885-5p o hsa-miR-671-3p > hsa-miR-518e-5p, hsa- hsa-miR-331-5p o hsa-miR-671-3p > hsa-miR-518e-5p, hsa- hsa-miR-885-5p o DESCRIPTION hsa-miR-671-3p > hsa-miR-518e-5p > hsa-miR-331-5p > hsa-miR-885-5p o hsa-miR-671-3p > hsa-miR-153-3p > hsa-miR-21-3p > hsa-miR-331-5p o hsa-miR-671-3p > hsa-miR-153-3p > hsa-miR-21-3p > hsa-miR-885-5p0hsa-miR-671-3p > hsa-miR-153-3p > hsa-miR-331-5p > hsa-miR-885-5p ohsa-miR-671-3p > hsa-miR-21-3p > hsa-miR-331-5p > hsa-miR-885-5p0hsa-miR-518e-5p, hsa-miR-153-3p > hsa-miR-21-3p > hsa-miR-331-5p o hsa-miR-518e-5p, hsa-miR-153-3p > hsa-miR-21-3p > hsa-miR-885-5p o hsa-miR-518e-5p, hsa-miR-153-3p > hsa-miR-331-5p > hsa-miR-885-5p o hsa-miR-518e-5p, hsa-miR-21-3p > hsa-miR-331-5p > hsa-miR-885-5p o hsa-miR-153-3p > hsa-miR-21-3p > hsa-miR-331-5p^ hsa-miR-885-5p o
[0004] 3) Preferably, the urinary miRNA markers can be selected from at least two of the following three miRNAs: hsa-miR-671-3p > hsa-miR-518e-5p, hsa-miR-153-3p o hsa-miR-671-3p > hsa-miR-518e-5p, hsa-miR-21-3p o hsa-miR-671-3p > hsa-miR-518e-5p, hsa-miR-331-5p o hsa-miR-671-3p > hsa-miR-518e-5p, hsa-miR-885-5p o hsa-miR-671-3p > hsa-miR-153-3p > hsa-miR-21-3p o hsa-miR-671-3p > hsa-miR-153-3p > hsa-miR-331-5p o hsa-miR-671-3p > hsa-miR-153-3p > hsa-miR-885-5p o hsa-miR-671-3p > hsa-miR-21-3p > hsa-miR-331-5p ohsa-miR-671-3p > hsa-miR-21-3p > hsa-miR-885-5p o hsa-miR-518e-5p, hsa-miR-153-3p > hsa-miR-21-3p o hsa-miR-518e-5p, hsa-miR-153-3p > hsa-miR-331-5p o hsa-miR-518e-5p, hsa-miR-153-3p > hsa-miR-885-5p o hsa-miR-518e-5p, hsa-miR-21-3p > hsa-miR-331-5p o hsa-miR-518e-5p, hsa-miR-21-3p ^ hsa-miR-885-5p o hsa-miR-153-3p > hsa-miR-21-hsa-miR-518e-5p > hsa-miR-331-5p0hsa-miR-518e-5p > hsa-miR-885-5p0hsa-miR-153-3p > hsa-miR-21-3p o Instructions hsa-miR-153-3p> hsa-miR-331-5p o hsa-miR-21-3p> hsa-miR-331-5p o hsa-miR-21-3p> hsa-miR-885-5p o
[0006] 5) Preferably, the urine miRNA marker can be selected from the following miRNA: hsa-miR hsa-miR In some The invention is characterized in that: when the urine miRNA marker can be selected from at least two of the eight miRNAs hsa-miR-671-3p, hsa-miR-518e-5p, hsa-miR-153-3p, hsa-miR-21-3p, hsa-miR-331-5p, hsa-miR-885-5p, hsa-miR-4306, and hsa-miR-1-3p; or when the urine miRNA marker can be selected from at least two of the seven miRNAs hsa-miR-671-3p, hsa-miR-518e-5p, hsa-miR-153-3p, hsa-miR-21-3p, hsa-miR-331-5p, hsa-miR-885-5p, and hsa-miR-4306, Or when the urine miRNA marker can be selected from at least two of the seven miRNAs hsa-miR-671-3p, hsa-miR-518e-5p, hsa-miR-153-3p, hsa-miR-21-3p, hsa-miR-331-5p, hsa-miR-885-5p, and hsa-miR-1-3p, or when the urine miRNA marker can be selected from at least two of the six miRNAs hsa-miR-671-3p, hsa-miR-518e-5p, hsa-miR-153-3p, hsa-miR-21-3p, hsa-miR-331-5p, and hsa-miR-885-5p, one of the miRNAs must be hsa-miR-518e-5p. In some preferred embodiments, The present invention also provides a urine miRNA marker containing a specific miRNA, wherein: when the urine miRNA marker can be selected from at least two of the eight miRNAs hsa-miR-671-3p, hsa-miR-518e-5p, hsa-miR-153-3p, hsa-miR-21-3p, hsa-miR-331-5p, hsa-miR-885-5p, hsa-miR-4306, and hsa-miR-1-3p; or when the urine miRNA marker can be selected from at least two of the seven miRNAs hsa-miR-671-3p, hsa-miR-518e-5p, hsa-miR-153-3p, hsa-miR-21-3p, hsa-miR-331-5p, hsa-miR-885-5p, and hsa-miR-1-3p. Hour,Or one of the miRNAs must be hsa-miR-1-3p. In the present invention, at least two of the eight miRNAs selected from the group consisting of hsa-miR-671-3p, hsa-miR-518e-5p, hsa-miR-153-3p, hsa-miR-21-3p, hsa-miR-331-5p, hsa-miR-885-5p, hsa-miR-4306, and hsa-miR-1-3p are included, and a specific miRNA (e.g., hsa-miR-518e-5p or hsa-miR-1-3p) is included. ? The urine miRNA markers formed, with an AUC value of not less than 0.681, include but are not limited to the following combinations, which can be used as preferred embodiments:
[0007] 1) Preferably, the urine miRNA markers can be selected from at least two of the following eight miRNAs: hsa-miR-671-3p, hsa-miR-518e-5p, hsa-miR-153-3p, hsa-miR-21-3p, hsa-miR-331-5p, hsa-miR-885-5p, hsa-miR-4306, and hsa-miR-1-3p.
[0008] 2) Preferably, the urine miRNA markers can be selected from at least two of the following seven miRNAs: hsa-miR-671-3p, hsa-miR-518e-5p, hsa-miR-153-3p, hsa-miR-21-3p, hsa-miR-331-5p, hsa-miR-885-5p, hsa-miR-4306; hsa-miR-671-3p, hsa-miR-518e-5p, hsa-miR-153-3p, hsa-miR-21-3p, hsa-miR-331-5p, hsa-miR-885-5p, hsa-miR-1-3p; hsa-miR-518e-5p, hsa-miR-153-3p, hsa-miR-21-3p, hsa-miR-331-5p, hsa-miR-885-5p, hsa-miR-4306; hsa-miR-331-5p ^ hsa-miR-885-5p ^ hsa-miR-4306, hsa-miR-l-3p;
[0009] 3) Preferably, the urinary miRNA markers can be selected from at least two of the following 6 miRNAs: hsa-miR-671-3p, hsa-miR-518e-5p, hsa-miR-153-3p, hsa-miR-21-3p, hsa-miR-331-5p, hsa-miR-4306; hsa-miR-671-3p, hsa-miR-518e-5p, hsa-miR-153-3p, hsa-miR-21-3p, hsa-miR-331-5p, hsa-miR-1-3p; hsa-miR-671-3p, hsa-miR-518e-5p, hsa-miR-153-3p, hsa-miR-21-3p, hsa-miR-331-5p, hsa-miR-885-5p; hsa-miR-671-3p, hsa-miR-518e-5p, hsa-miR-21-3p, hsa-miR-331-5p, hsa-miR-4306, hsa-miR-1-3p; hsa-miR-671-3p, hsa-miR-518e-5p, hsa-miR-21-3p, hsa-miR-331-5p, hsa-miR-885-5p, hsa-miR-4306; hsa-miR-671-3p, hsa-miR-518e-5p, hsa-miR-21-3p, hsa-miR-331-5p, hsa-miR-885-5p, hsa-miR-1-3p; hsa-miR-518e-5p, hsa-miR-153-3p, hsa-miR-21-3p, hsa-miR-331-5p, hsa-miR-4306, hsa-miR-1-3p; hsa-miR-518e-5p, hsa-miR-153-3p, hsa-miR-21-3p, hsa-miR-331-5p, hsa-miR-885-5p, hsa-miR-4306; hsa-miR-518e-5p, hsa-miR-153-3p, hsa-miR-21-3p, hsa-miR-885-5p, hsa-miR-4306, hsa-miR-1-3p; hsa-miR-518e-5p, hsa-miR-153-3p, hsa-miR-21-3p, hsa-miR-331-5p, hsa-miR-885-5p, hsa-miR-1-3p;hsa-miR-518e-5p、 hsa-miR-21-3p、 hsa-miR-331-5p、 hsa-miR-885-5p、 hsa-miR-4306、 hsa-miR-l-3p;
[0010] 4) Preferably, the urinary miRNA markers can be selected from at least two of the following five miRNAs: hsa-miR-671-3p, hsa-miR-518e-5p, hsa-miR-153-3p, hsa-miR-21-3p, hsa-miR-331-5p; hsa-miR-671-3p, hsa-miR-518e-5p, hsa-miR-153-3p, hsa-miR-21-3p, hsa-miR-885-5p; hsa-miR-671-3p, hsa-miR-518e-5p, hsa-miR-21-3p, hsa-miR-331-5p, hsa-miR-4306; hsa-miR-671-3p, hsa-miR-518e-5p, hsa-miR-21-3p, hsa-miR-331-5p, hsa-miR-1-3p; hsa-miR-671-3p, hsa-miR-518e-5p, hsa-miR-21-3p, hsa-miR-331-5p, hsa-miR-885-5p; hsa-miR-518e-5p, hsa-miR-153-3p, hsa-miR-21-3p, hsa-miR-331-5p, hsa-miR-4306; hsa-miR-518e-5p, hsa-miR-153-3p, hsa-miR-21-3p, hsa-miR-331-5p, hsa-miR-1-3p; hsa-miR-518e-5p, hsa-miR-153-3p, hsa-miR-21-3p, hsa-miR-331-5p, hsa-miR-885-5p; hsa-miR-518e-5p, hsa-miR-21-3p, hsa-miR-331-5p, hsa-miR-4306, hsa-miR-1-3p; hsa-miR-518e-5p, hsa-miR-21-3p, hsa-miR-331-5p, hsa-miR-885-5p, hsa-miR-4306; hsa-miR-518e-5p, hsa-miR-21-3p, hsa-miR-331-5p, hsa-miR-885-5p, hsa-miR-1-3p; Specification
[0011] 5) Preferably, the urine miRNA markers may be selected from at least two of the following four miRNAs: hsa-miR-671-3p > hsa-miR-518e-5p > hsa-miR-21-3p > hsa-miR-331-5p; hsa-miR-518e-5p, hsa-miR-153-3p > hsa-miR-21-3p > hsa-miR-331-5p; hsa-miR-518e-5p, hsa-miR-153-3p > hsa-miR-21-3p > hsa-miR-885-5p; hsa-miR-518e-5p, hsa-miR-21-3p > hsa-miR-331-5p > hsa-miR-4306; hsa-miR-518e-5p, hsa-miR-153-3p > hsa-miR-21-3p > hsa-miR-885-5p; hsa-miR-518e-5p, hsa-miR-21-3p > hsa-miR-331-5p > hsa-miR-4306; hsa-miR-21-3p> hsa-miR-331-5p> hsa-miR-l-3p; hsa-miR-518e-5p, hsa-miR-21-3p> hsa-miR-331-5p> hsa-miR-885-5p;
[0012] 6) Preferably, the urine miRNA marker can be selected from at least two of the following three miRNAs: hsa-miR-518e-5p > hsa-miR-21-3p > hsa-miR-331-5p; The following urine miRNA markers consisting of 3 to 8 miRNAs and having an AUC value of 30.681 have the common feature that they all include at least hsa-miR-518e-5p, hsa-miR-21-3p, and hsa-miR-331-5p: In some preferred embodiments, the urine miRNA marker can be composed of the following eight miRNAs: hsa-miR-671-3p, hsa-miR-518e-5p, hsa-miR-153-3p, hsa-miR-21-3p, hsa-miR-331-5p, hsa-miR-885-5p> In some preferred embodiments, the urine miRNA marker may consist of the following seven miRNAs: hsa-miR-671-3p, hsa-miR-518e-5p, hsa-miR-153-3p, hsa-miR-21-3p, hsa-miR-331-5p, hsa-miR-885-5p, and hsa-miR-4306. In some preferred embodiments, the urine miRNA marker may consist of the following seven miRNAs: hsa-miR-671-3p, hsa-miR-518e-5p, hsa-miR-153-3p, hsa-miR-21-3p, hsa-miR-331-5p, hsa-miR-885-5p, and hsa-miR-1-3p. o In some preferred embodiments, the urine miRNA markers may be composed of the following six miRNAs: hsa-miR-671-3p, hsa-miR-518e-5p, hsa-miR-153-3p, hsa-miR-21-3p, hsa-miR-331-5p, hsa-miR-885-5p oIn some more preferred embodiments, the urine miRNA marker may be composed of the following 6 miRNAs: hsa-miR-671-3p > hsa-miR-518e-5p > hsa-miR-153-3p^ hsa-miR-21-3p^ hsa-miR-331-5p. In some more preferred embodiments, the urine miRNA marker may be composed of the following 4 miRNAs: hsa-miR-518e-5p > hsa-miR-21-3p > hsa-miR-331-5p > hsa-miR-1-3p. In some more preferred embodiments, the urine miRNA marker may be composed of the following 4 miRNAs: hsa-miR-518e-5p > hsa-miR-153-3p > hsa-miR-21-3p > hsa-miR-331-5p. o In some more preferred embodiments, the urine miRNA marker may be composed of the following three miRNAs: hsa-miR-518e-5p > hsa-miR-21-3p > hsa-miR-331-5p o The present invention also provides a renal cancer diagnostic reagent, including a reagent for specifically detecting one or more urinary miRNA markers as described above. Furthermore, the present invention also provides a renal cancer diagnostic kit, including one or more urinary miRNA markers as described above as standards, and corresponding primers for detecting the various urinary miRNA markers as described above. Furthermore, the present invention also provides a use of the various urinary miRNA markers as described above, primarily for preparing products for early diagnosis and / or recurrence monitoring. Such products include, but are not limited to, devices (such as oligonucleotide probes or their integration, high-throughput miRNA detection chips on chip substrates or detection substrates, and microfluidic detection chips), kits, and equipment. In some preferred embodiments, the prepared products for early diagnosis and / or recurrence monitoring include one or more of the following functions:
[0013] 1) Identify or assist in the identification of renal cancer;
[0014] 2) Diagnosis or auxiliary diagnosis of newly diagnosed renal cancer;
[0015] 3) Diagnosis or auxiliary diagnosis of recurrent renal cancer. Furthermore, the present invention provides a method for early diagnosis and / or recurrence monitoring of renal cancer using one or more urine miRNA markers as described above, comprising the following steps: Step 1: Detecting the presence of miRNA in a urine sample obtained from a subject; Step 2: Measuring the expression level of at least one miRNA among the miRNA markers in the urine sample; Step 3: Using a score based on the previously measured miRNA expression level to compare with a reference sample to determine whether there is a significant difference between the subject sample and the reference sample, thereby diagnosing and / or monitoring the possibility of renal cancer in the subject at an early stage. Also provided herein is a method for determining whether a subject has kidney cancer or determines a subject's risk of developing kidney cancer, the method comprising detecting the expression level of at least one miRNA in a urine sample obtained from the subject, wherein the at least one miRNA is selected from the group consisting of hsa-miR-671-3p, hsa-miR-518e-5p, hsa-miR-153-3p, hsa-miR-21-3p, hsa-miR-331-5p, hsa-miR-885-5p, hsa-miR-4306, and hsa-miR-1-3p; and wherein differential expression of the miRNA compared to a control indicates that the subject has kidney cancer or is at risk of developing kidney cancer. In some embodiments, the at least one miRNA comprises a combination of urine miRNA markers as described above. In some embodiments, the expression level of the miRNA is upregulated or downregulated in a subject having kidney cancer or at risk of developing kidney cancer compared to a control. In some embodiments, the control is selected from a subject without cancer, a subject without renal cancer, or a subject not having or at risk for developing renal cancer. In some embodiments, the methods provided herein further comprise performing clinical procedures and / or measuring additional biomarkers in biological samples (i.e., urine, tissue blood, plasma, or serum samples). Additional biomarkers may include, but are not limited to, carbonic anhydrase IX (CAIX), vascular endothelial growth factor (VEGF), hypoxia-inducible factor (HIF), KI67, P53, P21, PTEN (phosphatase and tensin homolog), E-cadherin, osteopontin, CD44, CXCR4, and other cell cycle and proliferation markers.Clinical procedures may include biopsy, fine needle aspiration, and diagnostic imaging tests, including but not limited to ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), or positron emission tomography (PET) imaging. In some embodiments, the present disclosure provides methods for treating subjects diagnosed with renal cancer using the methods disclosed herein. Subjects diagnosed with renal cancer will be referred to a licensed physician and, if determined appropriate, treated with appropriate anti-cancer compounds, surgery, targeted therapy, immunotherapy, or radiation therapy, or a combination of these therapies. Compared to the prior art, the present invention has the following advantages:
[0016] 1. This invention is the first to discover multiple miRNAs that can detect renal cancer, such as hsa-miR-518e-5p and hsa-miR-1-3p. No existing literature or patents have reported that these miRNAs can be used to detect renal cancer.
[0017] 2. The present invention initially identified 16 miRNA markers that can be used to detect renal cancer in urine samples from cancer and healthy control subjects. Further research led to the creative discovery that when urine miRNA markers were selected from one or more of the following eight miRNAs, renal cancer could be detected with significant differences (p<0.05): hsa-miR-671-3p > hsa-miR-518e-5p > hsa-miR-153-3p > hsa-miR-21-3p > hsa-miR-331-5p > hsa-miR-885-5p > hsa-miR-4306 > hsa-miR-1-3p
[0018] 3. The present invention also surprisingly discovered that a urine miRNA marker composed of at least two of the six miRNAs selected from the group consisting of hsa-miR-671-3p, hsa-miR-518e-5p, hsa-miR-153-3p, hsa-miR-21-3p, hsa-miR-331-5p, and hsa-miR-885-5p exhibits an AUC value that is higher than that of a single miRNA (e.g., hsa-miR-518e-5p). However, when the urine miRNA marker consists of hsa-miR-518e-5p and hsa-miR-153-3p, its AUC value is 0.561, which is lower than the AUC value of hsa-miR-518e-5p alone.
[0019] 4. Based on the research on a urine miRNA marker composed of 8 miRNAs (hsa-miR-671-3p, hsa-miR-518e-5p, hsa-miR-153-3p, hsa-miR-21-3p, hsa-miR-331-5p, hsa-miR-885-5p, hsa-miR-4306, and hsa-miR-1-3p) with an AUC of 0.681, the present invention unexpectedly found a urine miRNA marker with an AUC of 0.681 through optimization and screening. The common characteristics of the urine miRNA markers are: the urine miRNA markers are selected from hsa-miR-671-3p, hsa-miR-518e-5p, hsa-miR-153-3p, hsa-miR-21-3p, hsa-miR-331-5p, hsa-miR-885-5p, hsa-miR-4306, and hsa-miR-1-3p. At least two of the eight miRNAs listed as hsa-miR-885-5p, hsa-miR-4306, and hsa-miR-1-3p must be present, and one specific miRNA (hsa-miR-518e-5p or hsa-miR-1-3p) must be present, particularly hsa-miR-518e-5p, which has an upregulating effect. Therefore, the present invention explored the use of hsa-miR-671-3p, hsa-miR-518e-5p, hsa-miR-153-3p, hsa-miR-21-3p, hsa-miR-331-5p, and hsa-miR-885-5p as a new renal cancer marker combination. Clinical samples were collected and validated using this combination. The results demonstrated that this marker combination has significant value in the early detection and diagnosis of renal cancer. In summary, the present invention provides multiple combinations of urine miRNA markers with simple detection, strong feasibility, high sensitivity and specificity, and clinical diagnostic and guidance significance. Furthermore, the present invention can detect miRNA expression levels through urine, thus achieving a non-invasive purpose. Figure 1 shows a heatmap of the expression levels of eight differentially expressed (P < 0.05) renal cancer miRNA diagnostic markers. The miRNA expression levels (copies / mL) are presented on a log2 scale and normalized to a zero mean. The color of the dots indicates the concentration. Hierarchical clustering was performed on two dimensions (miRNA and sample) based on Euclidean distance. For the horizontal dimension, color is used to represent case-control subjects.Figure 2 shows the AUC plots of renal cancer miRNA diagnostic marker combinations in various cohorts; Figure 2-A shows the AUC plots of eight renal cancer miRNA diagnostic marker combinations in various cohorts, and Figure 2-B shows the AUC plots of six renal cancer miRNA diagnostic marker combinations in various cohorts. Figure 3 shows a box plot of the control and cancer prediction values of the six renal cancer miRNA diagnostic marker combinations. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS The technical solutions of the present invention are further described below through specific examples. Unless otherwise specified, all raw materials and equipment used in the present invention are commercially available or commonly used in the art. The methods in the following examples, unless otherwise specified, are conventional methods in the art. Definitions of Terms: The term "miRNA" refers to microRNAs, i.e., small non-coding RNA molecules, which, in some embodiments, contain approximately 22 nucleotides and are found in plants, animals, and some viruses. MiRNAs are known to function in RNA silencing and post-transcriptional regulation of gene expression. These highly conserved RNAs regulate gene expression by binding to the 3'-untranslated regions (3'-UTRs) of specific mRNAs. For example, each miRNA is thought to regulate multiple genes, and hundreds of miRNA genes are predicted to exist in higher eukaryotes. MiRNAs tend to be transcribed from several distinct loci in the genome. These genes encode long RNAs with hairpin structures that are then encoded by a series of RNA enzymes.
[0020] During processing by miRNAs (including Drosha and Dicer), miRNA duplexes, typically approximately 22 nucleotides long, are formed with a two-nucleotide overhang at the 3' end. The term "regulation" refers to the process by which a cell increases or decreases the amount of a cellular component, such as RNA or protein, in response to external variables. An increase in a cellular component is referred to as upregulation, while a decrease in a cellular component is referred to as downregulation. As used herein, the terms "dysregulation" or "misregulation" refer to either upregulation or downregulation. An example of downregulation is a decrease in the number of receptors in a cell for a molecule, such as a hormone or neurotransmitter, which reduces the cell's sensitivity to that molecule. This phenomenon is an example of a locally acting negative feedback mechanism. An example of upregulation is an increase in the number of cytochrome P450 enzymes in liver cells when xenobiotic molecules, such as dioxins, are administered, leading to greater degradation of these molecules. Upregulation and downregulation can also occur in response to toxins or hormones. An example of upregulation during pregnancy is a hormone that causes cells in the uterus to become more sensitive to oxytocin. The term "differential expression" refers to measuring a cellular component in comparison with a control or another sample to determine a difference in, for example, the concentration, presence, or intensity of the cellular component. The results of such a comparison can be given as an absolute value, i.e., the component is present in the sample but not in the control; or as a relative value, i.e., the expression or concentration of the component is increased or decreased compared to the control. In this context, the term "increase" is synonymous with and interchangeable with the term "upregulate," and the term "decrease" is synonymous with and interchangeable with the term "downregulate." The term "miRNA combination" refers to a combination of miRNAs of the present invention. The amount of miRNA can be determined in a sample from a subject using techniques known in the art. Depending on the nature of the sample, the amount can be determined using PCR-based techniques for quantifying polynucleotides or by other methods such as mass spectrometry or sequencing. The term "probe" refers to a single-stranded oligonucleotide typically used to detect a target RNA and / or RNA sequence that is complementary to the probe sequence. The probe is a single-stranded nucleic acid that allows nucleotide pairing due to complementarity between the probe and the target sequence.
[0021] (DNA or RNA) hybridization. The length of the probe depends on the intended use and the desired probe specificity. Typically, the probe is 20 to 500 (i.e., 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 300, 400, 500) nucleotides in length, preferably 20 to 100, and more preferably 20 to 50 nucleotides. For detection of microRNAs, the probe is 12 to 30 nucleotides in length. Probes are used in a variety of experimental settings, such as, but not limited to, Southern and Northern blotting, real-time PCR, in situ hybridization (ISH), and microarray experiments. Probes can be unlabeled, directly labeled, or indirectly labeled, such as with biotin to which a streptavidin complex can subsequently bind. The label can be a molecule detectable by spectroscopic, photochemical, biochemical, immunochemical, chemical, or other physical means. For example, suitable labels include 32P, fluorescent dyes, electron-dense reagents, enzymes (e.g., commonly used in ELISA), biotin, digoxigenin, or haptens, as well as other entities that are detectable or can be made detectable. The label can be introduced at any position in the nucleic acid, such as at the 3' end, 5' end, or internally. The term "probe" also encompasses nucleic acids with varying backbone compositions, such as, but not limited to, peptide nucleic acids (PNA), locked nucleic acids (LNA), glycol nucleic acids (GNA), and threose nucleic acids (TNA). The terms "indicator" and "marker" are used interchangeably herein to refer to a sign or signal of a condition or to be used to monitor a condition. Such "conditions" refer to the biological state of a cell, tissue, or organ, or to the healthy and / or diseased state of an individual. An indicator can be the presence or absence of molecules, including but not limited to peptides, proteins, and nucleic acids, or can be a change in the expression level or pattern of such molecules in a cell, tissue, organ, or individual. An indicator can be a sign of the onset, development, or presence of a disease in an individual, or further progression of such a disease. An indicator can also be a sign of the risk of developing a disease in an individual. The term "score" refers to an integer or number, which can be determined mathematically, for example, using computational models known in the art (including but not limited to SMV as an example), and calculated using any of the numerous mathematical equations and / or algorithms known in the art for statistical classification purposes.Such a score is used to enumerate a result over a range of possible outcomes. The relevance and statistical significance of such a score depends on the size and quality of the underlying data set used to establish the range of results. For example, a blind sample can be input into an algorithm, which then calculates a score based on the information provided by analyzing the blind sample. This generates a score for the blind sample. Based on this score, a decision can be made, such as how likely the patient who generated the blind sample is to have cancer or not. The end values of the range can be logically defined based on the data provided or arbitrarily defined according to the requirements of the experimenter. In both cases, the range needs to be defined before testing the blind sample. The term "expression level" refers to the amount of a gene product present in the body or sample at a specific time point. The expression level can be measured / quantified / detected, for example, by the protein or mRNA expressed by the gene. Expression levels can be quantified, for example, by normalizing the amount of the target gene product present in a sample with the total amount of the same type of gene product (total protein or mRNA) in the same sample or a reference sample (e.g., a sample obtained from the same individual at the same time or a portion of the same sample of the same size (weight, volume), or by determining the amount of the target gene product / defined sample size (weight, volume, etc.). Expression levels can be measured or detected by any method known in the art, such as methods for direct detection and quantification of the target gene product (e.g., mass spectrometry), or methods for indirect detection and measurement of the target gene product, which generally work by binding the target gene product to one or more distinct molecules or detection devices specific for the target gene product (e.g., primers, probes, antibodies, protein scaffolds).It is also known to those skilled in the art that determining the level of gene copies also includes determining the absence or presence of one or more fragments (e.g., using nucleic acid probes or primers, such as quantitative PCR, multiplex ligation-dependent probe amplification PCR). A method for detecting renal cancer comprises the following steps: a) measuring the level of hsa-miR-671-3p, hsa-miR-518e-5p, hsa-miR-153-3p, hsa-miR-21-3p, hsa-miR-331-5p, hsa-miR-885-5p in a test sample and a reference sample of human origin; b) comparing the level of hsa-miR-671-3p, hsa-miR-518e-5p, hsa-miR-153-3p, hsa-miR-21-3p, hsa-miR-331-5p, hsa-miR-885-5p in the test sample with that in the reference sample. The expression level of hsa-miR-885-5p is determined; wherein, a significant change in the expression level of any of the aforementioned miRNAs in the test sample compared to the expression level of the corresponding miRNA in the reference sample indicates that the individual may have renal cancer. Specifically, if the expression level of any one of the renal cancer miRNAs tested is significantly different from the expression level of the miRNA in the reference sample, the sample provider may have renal cancer. In a preferred embodiment, if the expression levels of any eight miRNAs in the urine sample tested are significantly different from the expression levels of the miRNAs in the reference sample, the sample provider may have renal cancer. In an even more preferred embodiment, if the expression levels of six miRNAs in the urine sample tested are significantly different from the expression levels of the miRNAs in the reference sample, the sample provider may have renal cancer. In the present invention, the reference sample is a urine sample from a healthy individual. In another aspect, the present invention also provides a method for detecting renal cancer microRNAs. Specifically, the method comprises reverse transcription and real-time quantitative polymerase chain reaction (RT-qPCR). More specifically, in the real-time fluorescent quantitative polymerase chain reaction, the primer combinations used were reverse transcription primers and PCR primer combinations for detecting hsa-miR-671-3p, hsa-miR-518e-5p, hsa-miR-153-3p, hsa-miR-21-3p, hsa-miR-331-5p, and hsa-miR-885-5p. The primer sequences of the present invention can be appropriately adjusted and modified based on the sequences of the relevant miRNAs. These modified primer sequences can still be used to detect the miRNA markers. The present invention also includes these equivalent technical solutions.The present invention utilizes RT-qPCR, which offers greater clinical feasibility and practicality compared to microarrays based on hundreds of molecules. Furthermore, it is low-cost and easily disseminated. Furthermore, the aforementioned miRNA detection methods are not limited to the RT-qPCR provided herein; other methods, such as sequencing, microarrays, Northern blotting, bioluminescence, and probe-based assays, can also be used to detect the aforementioned miRNA markers. The applicant has discovered in their research that any combination of one miRNA marker, or any combination of two to five miRNA markers, can be used to diagnose renal cancer. Using these markers, renal cancer can be reliably identified. The present invention further studied 16 miRNA markers that can detect renal cancer and found that 8 of them can detect renal cancer with significant differences (p < 0.05): hsa-miR-671-3p > hsa-miR-518e-5p, hsa-miR-153-3p > hsa-miR-21-3p, hsa-miR-331-5p, hsa-miR-885-5p, hsa-miR-4306, hsa-miR-1-3p; and further optimization and screening yielded a combination with a higher AUC value than the aforementioned 8 miRNA markers, namely, hsa-miR-671-3p, hsa-miR-518e-5p, hsa-miR-153-3p, hsa-miR-21-3p, hsa-miR-331-5p, hsa-miR-885-5p, hsa-miR-4306, and hsa-miR-1-3p. The kidney cancer marker combination, including the hsa-miR-885-5p combination, consists of multiple nucleic acid molecules, each encoding at least one miRNA sequence. Specific sequence information is shown in Table 1 below. All miRNA sequences disclosed in this invention are stored in the miRBase database (http: / / www.mirbase.org / ). Table 1. Sequence listing of eight miRNAs. The present invention discloses a renal cancer diagnostic marker combination comprising multiple nucleic acid molecules encoding hsa-miR-671-3p, hsa-miR-518e-5p, hsa-miR-153-3p, hsa-miR-21-3p, hsa-miR-331-5p, and hsa-miR-885-5p. The expression of any one, any two, any three, any four, any five, or any six of the nucleic acid molecules encoding hsa-miR-671-3p, hsa-miR-518e-5p, hsa-miR-153-3p, hsa-miR-21-3p, hsa-miR-331-5p, and hsa-miR-885-5p is significantly altered in the urine of patients diagnosed with renal cancer compared to their expression in controls. In an optimal embodiment for diagnosing renal cancer, the plurality of nucleic acid molecules described above includes a combination of six nucleic acid molecules: hsa-miR-671-3p, hsa-miR-518e-5p, hsa-miR-153-3p, hsa-miR-21-3p, hsa-miR-331-5p, and hsa-miR-885-5p. The miRNAs and methods disclosed herein are used to diagnose renal cancer. Thus, as a result of a determination based on the methods provided herein, a subject diagnosed with renal cancer using the methods described herein can receive necessary and relevant medications (e.g., chemotherapeutic agents) or be placed on a necessary treatment regimen, such as radiation therapy, surgical resection, targeted therapy, immunotherapy, etc., based on the diagnosis. Thus, the methods disclosed herein allow for the treatment of subjects diagnosed with renal cancer with compounds and compositions known in the art to be effective in treating renal cancer. Thus, in one embodiment, the methods disclosed herein allow a subject to be diagnosed with kidney cancer, wherein a treatment for kidney cancer as known in the art is then administered to the subject. The methods disclosed herein thus allow for the treatment of kidney cancer. The invention illustratively described herein may suitably be practiced in the absence of any element or elements, or limitation or limitations, not specifically disclosed herein. Thus, for example, the terms "comprising," "including," "containing," and the like should be read broadly and without limitation. Furthermore, the terms and expressions used herein have been used as terms of description rather than limitation, and there is no intention to exclude any equivalents of the features shown and described, or portions thereof, when used herein, but it should be recognized that various modifications are possible within the scope of the claimed invention.Therefore, it should be understood that while the present invention has been specifically disclosed through preferred embodiments and optional features, modifications and variations of the invention disclosed herein and embodied therein may be undertaken by those skilled in the art, and such modifications and variations are considered to fall within the scope of the present invention. Example 1: Validation Cohort Validation of an 8-miRNA Combination for Kidney Cancer Diagnosis I. Kidney Cancer Diagnostic Marker Combination Development Cohort Urine Sample Requirements: Collection and Extraction. The kidney cancer diagnostic marker study used two groups of samples: a case group consisting of 69 kidney cancer samples and a control group consisting of 88 healthy subjects. Biomarkers and biomarker combinations for detecting early kidney cancer were discovered and validated. Both kidney cancer cases and healthy subjects in the development cohort were obtained from the Second Affiliated Hospital, Zhejiang University School of Medicine. II. Reverse Transcription-Real-Time PCR Procedure and Results: Extraction was performed according to the Zymo Serum and Plasma Rapid cfDNA Extraction Kit protocol. After extraction, reverse transcription was performed using the MIRXE Reverse Transcription Kit protocol. After reverse transcription, qPCR amplification was performed for quality control. After quality control, samples were amplified by qPCR to measure the expression of 312 miRNAs. No significant stratification of expression was observed between cancer and healthy controls. Initially, 16 miRNA biomarkers for kidney cancer were identified. Further analysis revealed eight significantly differentially expressed miRNA biomarkers for kidney cancer, with adjusted P values less than 0.05. Three of these miRNAs were upregulated in kidney cancer subjects, while five were downregulated. The upregulated miRNAs included hsa-miR-518e-5p, hsa-miR-153-3p, and hsa-miR-21-3p. Downregulated miRNAs included hsa-miR-671-3p, hsa-miR-4306, hsa-miR-331-5p, hsa-miR-1-3p, and hsa-miR-885-5p. oHeatmaps of these eight miRNAs were generated by extracting them from the R&D cohort, revealing significant differences in miRNA expression between cancer and control subjects, as shown in Figure 1. III. Validation of the Eight MiRNAs in a Validation Cohort A leave-one-out cross-validation approach was used to test these eight urine miRNA biomarkers in a case-control cohort. The validation cohort consisted of 157 samples, achieving a diagnostic efficacy (AUC) of 0.681, as shown in Figure 2-A. Example 2: Validation Cohort Validation of the Optimal Six-miRNA Combination for Renal Cancer Diagnosis. The urine sample requirements, collection and extraction procedures, and reverse transcription-real-time fluorescence PCR procedures and results for the development cohort were the same as those described in Example 1. Based on the eight miRNAs previously screened, miRNA combinations were optimized using algorithms such as Lasso, Stepwise, and exhaustive search. Ultimately, six optimal miRNA combinations were identified. Leave-one-out cross-validation was then used to validate six urine biomarker combinations, including hsa-miR-671-3p, hsa-miR-518e-5p, hsa-miR-153-3p, hsa-miR-21-3p, hsa-miR-331-5p, and hsa-miR-885-5p. The validation cohort consisted of 157 samples. The diagnostic efficacy of the six-miRNA combination in the validation cohort was AUC = 0.703, as shown in Figure 2-B. The results of the model interpretation are shown in Figure 3. It can be seen that the model output probability for cancer patients is significantly higher than that for control subjects, indicating that the model can effectively predict and classify cancer patients and control subjects. Based on the above comparison, the six miRNA combinations are confirmed as one of the preferred combinations for diagnosing renal cancer. Example 3: Optimization of miRNA Combinations In this example, the AUC values of multivariate miRNA combinations were determined using the same leave-one-out cross-validation method as in Examples 1 and 2.AUC values for the multi-miRNA panel in the validation cohort were calculated for the eight miRNAs used in clinical trials (hsa-miR-671-3p, hsa-miR-518e-5p, hsa-miR-153-3p, hsa-miR-21-3p, hsa-miR-331-5p, hsa-miR-885-5p, hsa-miR-4306, and hsa-miR-1-3p). One miRNA was randomly selected as an invariant. Using this invariant miRNA as a benchmark, the average AUC values for multivariate combinations of 1, 2, 3, 4, 5, 6, 7, or 8 miRNAs were tested. The results are shown in Table 2. The average AUC from training and testing was calculated for each miRNA based on the results of cross-validation experiments involving 2 to 8 miRNAs (Table 2). When used individually, the eight miRNAs we identified were able to identify subjects with or at risk for developing kidney cancer. Combining two or more of these miRNAs further increased the AUC values. As shown in Table 2, when three or more miRNAs were combined, most multivariate miRNA combinations achieved high AUC values. Table 2. Average AUC values for individual miRNAs or combinations of up to eight miRNAs.
[0022] 2. Combinations of miRNAs for Renal Cancer Diagnosis To further validate the utility of miRNA combinations for renal cancer diagnosis, exemplary combinations containing the miRNAs listed in Table 2 were analyzed. The mean AUC, mean sensitivity, mean specificity, mean positive predictive value (PPV), and mean negative predictive value (NPV) for the validation cohort are shown in Table 3. Example combinations containing 1-8 miRNA signatures were used to predict and classify cancer patients and control subjects, with mean AUCs ranging from 0.553 to 0.681. Table 3. Mean AUC, Sensitivity, Specificity, Positive Predictive Value, and Negative Predictive Value for 1-8 Feature Combinations As examples in the specification, these miRNAs demonstrated good performance in both the test and validation cohorts. One or more of these miRNAs were then selected and combined with other miRNAs. The example combination with hsa-miR-518e-5p as the fixed miRNA significantly increased the AUC (Table 4) after adding more miRNAs (including the other miRNAs listed in Table 2). However, after adding more than six miRNAs, the AUC began to decrease slightly. Example combinations with hsa-miR-1-3p and hsa-miR-671-3p are shown in Tables 5 and 6, respectively. The AUC gradually increased with increasing the number of miRNAs in the combination, but began to decrease after exceeding six. Taking hsa-miR-518e-5p as an example, we compared single hsa-miR-518e-5p with multivariate miRNA combinations consisting of hsa-miR-518e-5p and adding one, two, three, four, five, or six of the remaining seven miRNAs. The mean AUC values were measured and the differences in AUC values were analyzed. The results are shown in Table 4. Table 4. Analysis of the differences in parameters between hsa-miR-518e-5p and the above-selected miRNA signature combinations: mean AUC, sensitivity, specificity, positive predictive value, and negative predictive value. Taking hsa-miR-1-3p as an example, we compared single hsa-miR-1-3p with multivariate miRNA combinations consisting of hsa-miR-1-3p and adding one, two, three, four, five, or six of the remaining seven miRNAs. The average AUC values were measured and the differences in AUC values were analyzed. The results are shown in Table 5. Table 5. Analysis of the differences in parameters between hsa-miR-1-3p and the above-selected miRNA signature combinations: average AUC, sensitivity, specificity, positive predictive value, and negative predictive value. Taking hsa-miR-671-3p as an example, the AUC values of hsa-miR-671-3p alone and multivariate miRNA combinations consisting of one, three, four, five, or six miRNAs selected from the remaining seven miRNAs and hsa-miR-671-3p were compared to analyze the differences in AUC values. The results are shown in Table 6. 6. Average AUC, sensitivity, specificity, positive predictive value, and negative predictive value of hsa-miR-671-3p compared with the above miRNA signature combinations To better illustrate that the various miRNA combinations provided by the present invention all have good AUCs, the present invention lists several miRNA combinations with an AUC of 0.681, as shown in Table 7. The common feature is that the miRNA combinations shown in No. 1 to No. 32 all contain hsa-miR-518e-5p. However, this does not mean that the scope of miRNA combinations protected by the present invention is limited to the scope of Table 7. Table 7. Exemplary miRNA combinations and their respective AUCs manual The present invention establishes a complete workflow for discovering and validating urine miRNA biomarker combinations and has successfully identified biomarkers and biomarker combinations for detecting renal cancer. It should be noted that the urine miRNA marker combinations provided by the present invention are derived through statistical analysis, screening, and analysis of clinical trial data from human urine samples. Therefore, they are suitable for highly population-specific detection and miRNA combinations with significantly differential expression by AUC. However, this does not mean that such miRNA combinations are universally applicable to the detection of human plasma or tissue samples. The above-described embodiment is merely a preferred embodiment of the present invention and does not constitute any limitation thereto. Other variations and modifications are possible without departing from the technical solutions set forth in the claims.
[0023] manual
[0024] SEQUENCE LISTING
[0025] <h0>Mirui (Hangzhou) Biotechnology Co., Ltd.; Mirui Laboratory Pte Ltd
[0026] <120> Urine miRNA markers, diagnostic reagents, and kits for kidney cancer diagnosis
[0027] <130> 2021.12
[0028] <160> 8
[0029] <170> Patentin version 3.3
[0030] <210> 1
[0031] <211> twenty two
[0032] <212> RNA
[0033] <213> Artificial sequence
[0034] <400> 1 cucuagaggg aagcgcuuuc ug 22
[0035] <210> 2
[0036] <211> 17
[0037] <212> RNA
[0038] <213> Artificial sequence
[0039] <400> 2 uggagagaaa ggcagua 17
[0040] <210> 3
[0041] <211> twenty one
[0042] <212> RNA
[0043] <213> Artificial sequence
[0044] <400> 3 caacaccagu cgaugggcug u 21
[0045] <210> 4
[0046] <211> twenty two
[0047] <212> RNA
[0048] <213> Artificial sequence
[0049] <400> 4 uggaauguaa agaaguaugu au 22
[0050] <210> 5 Instructions
[0051] <211> twenty one
[0052] <212> RNA
[0053] <213> Artificial sequence
[0054] <400> 5 uccgguucuc agggcuccac c 21
[0055] <210> 6
[0056] <211> twenty two
[0057] <212> RNA
[0058] <213> Artificial sequence
[0059] <400> 6 uugcauaguc acaaaaguga uc 22
[0060] <210> 7
[0061] <211> twenty two
[0062] <212> RNA
[0063] <213> Artificial sequence
[0064] <400> 7 cuagguaugg ucccagggau cc 22
[0065] <210> 8
[0066] <211> twenty two
[0067] <212> RNA
[0068] <213> Artificial sequence
[0069] <400> 8 uccauuacac uacccugccu cu 22
Claims
Claims 1. A urine miRNA marker for diagnosing renal cancer, characterized in that: One or more of the following miRNAs: hsa-miR-518e-5p, hsa-miR-671-3p, hsa-miR-153-3p, hsa-miR-21-3p, hsa-miR-331-5p, hsa-miR-885-5p, hsa-miR-4306, hsa-miR-1-3p o 2. The urine miRNA marker for kidney cancer diagnosis according to claim 1, wherein The miRNA marker is selected from one or more of the following miRNAs: hsa-miR-518e-5p, hsa-miR-671-3p, hsa-miR-153-3p, hsa-miR-21-3p, hsa-miR-331-5p, hsa-miR-885-5p, and hsa-miR-1-3p. o 3. The urine miRNA marker for diagnosing renal cancer according to claim 1, wherein The miRNA marker is selected from one or more of the following miRNAs: hsa-miR-518e-5p, hsa-miR-671-3p, hsa-miR-153-3p, hsa-miR-21-3p, hsa-miR-331-5p, hsa-miR-885-5p, hsa-miR-4306.
4. The urine miRNA marker for kidney cancer diagnosis according to claim 1, wherein The miRNA marker is selected from one or more of the following miRNAs: hsa-miR-518e-5p, hsa-miR-671-3p, hsa-miR-153-3p, hsa-miR-21-3p, hsa-miR-331-5p, and hsa-miR-885-5p. o 5. The urine miRNA marker for diagnosing renal cancer according to any one of claims 1 to 4, characterized in that When there are at least two miRNA markers, one of the miRNAs must be hsa-miR-518e-5p o 6. The urine miRNA marker for diagnosing renal cancer according to any one of claims 1 to 4, wherein When there are at least two miRNA markers, one of the miRNAs must be hsa-miR-1-3p o 7. The urine miRNA marker for diagnosing renal cancer according to claim 1, wherein The miRNA markers include any one or more combinations of the following: consisting of hsa-miR-671-3p> hsa-miR-518e-5p> hsa-miR-153-3p> hsa-miR-21-3p> hsa-miR-331-5p> hsa-miR-885-5p> hsa-miR-4306, and hsa-miR-1-3p; or consisting of hsa-miR-671-3p> hsa-miR-518e-5p> hsa-miR-153-3p> hsa-miR-21-3p> hsa-miR-331-5p> hsa-miR-885-5p> hsa-miR-4306; or consisting of hsa-miR-671-3p> hsa-miR-518e-5p> hsa-miR-153-3p> hsa-miR-21-3p> hsa-miR-331-5p> hsa-miR-885-5p> hsa-miR-4306; hsa-miR-153-3p > hsa-miR-21-3p > hsa-miR-331-5p > hsa-miR-885-5p > hsa-miR-1-3p; or consisting of hsa-miR-518e-5p, hsa-miR-153-3p, hsa-miR-21-3p, hsa-miR-331-5p, hsa-miR-885-5p, and hsa-miR-4306; or consisting of hsa-miR-671-3p, hsa-miR-518e-5p, hsa-miR-153-3p, hsa-miR-21-3p, hsa-miR-331-5p, and hsa-miR-4306; or consisting of hsa-miR-671-3p> hsa-miR-518e-5p> hsa-miR-153-3p> hsa-miR-21-3p> hsa-miR-331-5p> hsa-miR-1-3p; or consisting of hsa-miR-671-3p> hsa-miR-518e-5p> hsa-miR-153-3p> hsa-miR-21-3p> hsa-miR-331-5p> Claims consisting of hsa-miR-885-5p; or consisting of hsa-miR-671-3p> hsa-miR-518e-5p> hsa-miR-21-3p> hsa-miR-331-5p> hsa-miR-4306> hsa-miR-1-3p; or consisting of hsa-miR-671-3p> hsa-miR-518e-5p> hsa-miR-21-3p> hsa-miR-331-5p> hsa-miR-885-5p> hsa-miR-4306; or consisting of hsa-miR-671-3p> hsa-miR-518e-5p> hsa-miR-21-3p^ hsa-miR-331-5p> hsa-miR-885-5p> hsa-miR-1-3p; or consisting of hsa-miR-518e-5p> hsa-miR-153-3p> hsa-miR-21-3p> hsa-miR-331-5p> hsa-miR-4306> hsa-miR-1-3p; or hsa-miR-518e-5p> hsa-miR-153-3p> hsa-miR-21-3p, hsa-miR-331-5p> hsa-miR-885-5p> hsa-miR-4306; or hsa-miR-518e-5p> hsa-miR-153-3p> hsa-miR-21-3p> hsa-miR-331-5p> hsa-miR-885-5p> hsa-miR-1-3p; or consisting of hsa-miR-518e-5p, hsa-miR-21-3p, hsa-miR-331-5p, hsa-miR-885-5p, hsa-miR-4306, hsa-miR-1-3p; or consisting of hsa-miR-671-3p, hsa-miR-518e-5p, hsa-miR-153-3p, hsa-miR-21-3p, hsa-miR-331-5p; or consisting of hsa-miR-671-3p, hsa-miR-518e-5p, hsa-miR-153-3p, hsa-miR-21-3p, hsa-miR-885-5p; or consisting of hsa-miR-671-3p, hsa-miR-518e-5p, hsa-miR-153-3p, hsa-miR-21-3p, hsa-miR-885-5p hsa-miR-518e-5p > hsa-miR-21-3p^ hsa-miR-331-5p^ hsa-miR-4306;or consisting of hsa-miR-671-3p> hsa-miR-518e-5p> hsa-miR-21-3p> hsa-miR-331-5p, hsa-miR-1-3p; or consisting of hsa-miR-671-3p> hsa-miR-518e-5p> hsa-miR-21-3p> hsa-miR-331-5p> hsa-miR-885-5p; or consisting of hsa-miR-518e-5p> hsa-miR-153-3p> hsa-miR-21-3p, hsa-miR-331-5p, hsa-miR-4306; or consisting of hsa-miR-518e-5p> hsa-miR-153-3p> hsa-miR-21-3p> hsa-miR-331-5p> hsa-miR-1-3p; or consisting of hsa-miR-518e-5p> hsa-miR-153-3p> hsa-miR-21-3p, hsa-miR-331-5p> hsa-miR-885-5p; or consisting of hsa-miR-518e-5p hsa-miR-21-3p, hsa-miR-331-5p, hsa-miR-4306, hsa-miR-1-3p; or consisting of hsa-miR-518e-5p> hsa-miR-21-3p> hsa-miR-331-5p, hsa-miR-885-5p, hsa-miR-4306; or; The claims consist of hsa-miR-518e-5p, hsa-miR-21-3p, hsa-miR-331-5p, hsa-miR-885-5p, hsa-miR-1-3p; or consist of hsa-miR-671-3p, hsa-miR-518e-5p> hsa-miR-21-3p, hsa-miR-331-5p; or consist of hsa-miR-518e-5p> hsa-miR-153-3p, hsa-miR-21-3p, hsa-miR-331-5p; or consist of hsa-miR-518e-5p> hsa-miR-153-3p, hsa-miR-21-3p, hsa-miR-885-5p; Or it is composed of hsa-miR-518e-5p> hsa-miR-21-3p, hsa-miR-331-5p, hsa-miR-4306; or it is composed of hsa-miR-518e-5p> hsa-miR-21-3p, hsa-miR-331-5p, hsa-miR-l-3p; or it is composed of hsa-miR-518e-5p> hsa-miR-21-3p, hsa-miR-331-5p, hsa-miR-885-5p; or it is composed of hsa-miR-518e-5p, hsa-miR-21-3p, hsa-miR-331-5p.
8. A diagnostic reagent for renal cancer, characterized in that: A reagent comprising a specific detection of a urine miRNA marker according to any one of claims 1 to 7 9. A kit for diagnosing renal cancer, characterized in that: Comprising the urine miRNA marker according to any one of claims 1 to 7 as a standard, and corresponding primers for detecting the urine miRNA marker according to any one of claims 1 to 7.
10. A use of a urine miRNA marker according to any one of claims 1 to 7, characterized in that: For preparing products for early diagnosis and / or recurrence monitoring; preferably, including one or more of the following functions: 1) Identify or assist in the identification of renal cancer; 2) Diagnosis or auxiliary diagnosis of newly diagnosed renal cancer; 3) Diagnosis or auxiliary diagnosis of recurrent renal cancer.
11. A method for early diagnosis and / or recurrence monitoring of renal cancer using the urine miRNA marker according to any one of claims 1 to 7, characterized in that: The method comprises the following steps: step 1, detecting the presence of miRNA in a urine sample obtained from a subject; step 2, measuring the expression level of at least one miRNA in a miRNA marker in the urine sample; and step 3, using a score based on the previously measured miRNA expression level to diagnose early and / or monitor recurrence the possibility of the subject having kidney cancer.
